Lexaria Bioscience (LEXX) Asset Writedowns and Impairment (2010 - 2026)
Lexaria Bioscience (LEXX) posted Asset Writedowns and Impairment of -$7331.0 for Q1 2026, down 200.0% sequentially from $7331.0 in Q4 2025, and down 205.62% YoY from $6941.0 in Q1 2025.
Lexaria Bioscience (LEXX) Asset Writedowns and Impairment (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Asset Writedowns and Impairment for 12 years, with the latest figure at -$7331.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 205.62% year-over-year to -$7331.0 in Q1 2026, while the trailing twelve-month figure through May 2026 was -$280904.0 (down 1736.02% YoY) and the FY2025 annual result came in at -$247364.0, down 3287.68% from the prior year.
- Asset Writedowns and Impairment declined to -$7331.0 in Q1 2026 per LEXX's latest filing, from $7331.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $19781.0 in Q2 2025 and troughed at -$280904.0 in Q3 2025.
- A 5-year average of -$20926.5 and a median of $6941.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2022 and 2025: Asset Writedowns and Impairment jumped 1232.91% in 2022, then sank 1615.97% in 2025.
- Over 5 years, Asset Writedowns and Impairment stood at $10104.0 in 2022, then increased by 7.69% to $10881.0 in 2023, then sank by 37.34% to $6818.0 in 2024, then climbed by 7.52% to $7331.0 in 2025, then slumped by 200.0% to -$7331.0 in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$7331.0, $7331.0, and -$280904.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -7,331.00 |
| Feb 28, 2026 | -7,331.00 |
| Nov 30, 2025 | 7,331.00 |
| Nov 30, 2025 | 7,331.00 |
| Aug 31, 2025 | -280,904.00 |
| Aug 31, 2025 | -280,904.00 |
| May 31, 2025 | 19,781.00 |
| May 31, 2025 | 19,781.00 |
| Feb 28, 2025 | 6,941.00 |
| Feb 28, 2025 | 6,941.00 |
| Nov 30, 2024 | 6,818.00 |
| Nov 30, 2024 | 6,818.00 |
| Aug 31, 2024 | -16,370.00 |
| Aug 31, 2024 | -16,370.00 |
| May 31, 2024 | 6,681.00 |
| May 31, 2024 | 6,681.00 |
| Feb 29, 2024 | 6,568.00 |
| Feb 29, 2024 | 6,568.00 |
| Nov 30, 2023 | 10,881.00 |
| Nov 30, 2023 | 10,881.00 |